New imaging system could track cancer growth

NewsGuard 100/100 Score

A new imaging system currently entering clinical testing could allow doctors to track the process of cancer growth in real-time, scientists have said.

The system, based on a technique called positron emission tomography (PET) scanning, allows doctors to visualise the formation of new blood vessels in the body - a process called angiogenesis.

This occurs naturally during wound healing, when blood vessels have been damaged, but is also a crucial for cancers as they attempt to take in more nutrients and oxygen in order to grow.

Researchers said they would be able to track tumour growth by using a chemical that has been designed to bind to and highlight the process of angiogenesis.

This would be particularly useful in allowing doctors to monitor the effectiveness of treatment.

"Data from this program could establish a new measurement used to assess the effectiveness of treatment approaches in cancer," said lead researcher Dr David Brooks.

"Angiogenesis is a characteristic process of many cancers, and we're excited to participate in this clinical trial, which may provide additional validation for the use of this novel molecular imaging agent in oncology applications."

Cancer Research UK welcomed the study, said cancer information officer at the charity Josephine Querido.

"Being able to visualise this in real time in patients would be an important step forward and could have important implications for how the success of cancer treatment is monitored in future. We look forward to the results of this clinical trial," she said.

The research is being conducted by the Hammersmith Hospital in London in association with GE Healthcare.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis